Monday, January 30, 2012
Roche already has the broadest set of molecular diagnostic
technologies in the industry, and the pharma hopes acquiring Illumina
Inc. will give it access to the biggest potential growth area in the
MDx space: whole genome sequencing as routine clinical practice.
That is why Roche offered $5.7
billion in a hostile bid for Illumina, although the final price will certainly
be higher. Indeed, the biotech ended the week with a $6.3 billion market cap in
shareholder anticipation of a white knight or an increased bid from Roche.